Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.

Trial Details

NCT ID

NCT06771609

Phase

PHASE2

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• Adebrelimab + VEX metronomic chemotherapy + radiotherapy
• Adebrelimab + VEX metronomic chemotherapy

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723
• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Subjects are eligible to be included in the study only if all of the following criteria apply:
• Male or female who is 18 years of age or older on the day of signing the informed consent form.
• Subjects with metastatic triple-negative breast cancer, with clear clinical data records; specific reference to the "American Society of Clinical O…
• Have received less than or equal to 1 line of chemotherapy for metastatic breast cancer;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.